Satellos receives U.S. patent for forazapadin, valid until 2044 Oct 5, 2026 07:02AM
Satellos wins FDA clearance for forazapadin in second muscle disease Sep 24, 2026 07:01AM
Satellos Bioscience Inc. (MSLE) PT Raised to $18 at H.C. Wainwright Jul 9, 2026 06:52AM
Satellos reports 6-month interim data for DMD drug candidate SAT-3247 Jul 8, 2026 06:34AM
Guggenheim Starts Satellos Bioscience Inc. (MSLE) at Buy Apr 28, 2026 06:09AM


Apr 6, 2026 06:21AM Leerink Partners Starts Satellos Bioscience Inc. (MSLE) at Outperform
Mar 11, 2026 06:10AM Cantor Fitzgerald Starts Satellos Bioscience Inc. (MSLE) at Overweight